J&J/Ethicon Bets On Minimally Invasive CABG With $81 Mil. Heartport Buy
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's Ethicon subsidiary signaled its confidence in the future of minimally invasive coronary artery bypass grafting (CABG) with its Jan. 26 agreement to buy Heartport, Inc. for $81 mil.